Skip to main content
Log in

The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

In this paper we describe 4 new monoclonal antibodies to be applied in rat models for cancer. The monoclonal antibodies were obtained by immunizing Balb/c mice with CC531 rat colon adenocarcinoma cells. Hybridomas were produced and 4 were selected for their reactivity with CC531 in vitro (MG1, 2, 3 and 4). All 4 antibodies recognized other rat tumour cell lines and showed limited cross-reactivity with normal rat tissues. Intraperitoneally injected MG1, 2 and 4 homed to in vivo growing, artificially induced CC531 liver metastases. In these in vivo experiments, limited cross-reactivity with normal rat tissues, predominantly of the gastro-intestinal tract, was found. MG4 was found to enhance lysis of CC531 tumour cells mediated by IL-2 activated, cultured natural killer cells. These antibodies are potentially useful for antibody-based laboratory techniques and for investigation of antibody-based immunotherapy of cancer in a rat model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beun GDM, Van de Velde CJH, Fleuren GJ et al. T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. IV. Tumor neutralization in Winn type assays. J Immunother 1993; 14: 11–15.

    PubMed  CAS  Google Scholar 

  2. Beun GDM, van Eendenburg JDH, Corver WE et al. T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. I. Significant bispecific lysis of syngeneic colon carcinoma CC531 is critically dependent on prolonged preactivation of effector T-lymphocytes by immobilized anti-T-cell receptor antibody. J Immunother 1992; 11: 238–48.

    PubMed  CAS  Google Scholar 

  3. Giezeman-Smits KM, Gorter A, Nagelkerke JF et al. Characterization of three new membrane structures on rat NK cells which are involved in activation of the lytic machinery. Immunobiology 1997; 197: 429–43.

    PubMed  CAS  Google Scholar 

  4. Giezeman-Smits KM, Kuppen PJK, Ensink NG et al. The role of MHC class I expression in rat NK cell-mediated lysis of syngeneic tumor cells and virus-infected cells. Immunobiology 1996; 195: 286–99.

    PubMed  CAS  Google Scholar 

  5. Griffini P, Smorenburg SM, Verbeek FJ et al. Three-dimensional reconstruction of colon carcinoma metastases in liver. J Microsc 1997; 187: 12–21.

    Article  PubMed  Google Scholar 

  6. Hagenaars M, Ensink NG, Koelemij R et al. Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration. Int J Cancer 1998; 75: 233–8.

    Article  PubMed  CAS  Google Scholar 

  7. Heriot AG, Kumar D. Adjuvant therapy for resectable rectal and colonic cancer. Br J Surg 1998; 85: 300–9.

    Article  PubMed  CAS  Google Scholar 

  8. Koelemij R, Kuppen PJK, Van de Velde CJH et al. Bispecific antibodies in cancer therapy, from the laboratory to the clinic. J Immunother 1999; 22: 514–24.

    PubMed  CAS  Google Scholar 

  9. Kuppen PJK, Basse PH, Goldfarb RH et al. The infiltration of experimentally induced lung metastases of colon carcinoma CC531 by adoptively transferred interleukin-2-activated natural killer cells in Wag rats. Int J Cancer 1994; 56: 574–9.

    PubMed  CAS  Google Scholar 

  10. Marinelli A, van Dierendonck JH, van Brakel GM et al. Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion. Br J Cancer 1991; 64: 1069–75.

    PubMed  CAS  Google Scholar 

  11. Marquet RL, Westbroek DL and Jeekel J. Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer 1984; 33: 689–92.

    PubMed  CAS  Google Scholar 

  12. Riethmüller G, Schneider-Gädicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343: 1177–83.

    Article  PubMed  Google Scholar 

  13. Smits KM, Kuppen PJK, Eggermont AMM et al. Rat interleukin-2-activated natural killer (A-NK) cell-mediated lysis is determined by the presence of CD18 on A-NK cells and the absence of major histocompatibility complex class I on target cells. Eur J Immunol 1994; 24: 171–5.

    PubMed  CAS  Google Scholar 

  14. Stocchi L and Nelson H. Diagnostic and therapeutic applications of monoclonal antibodies in colorectal cancer. Dis Colon Rectum 1998; 41: 232–50.

    Article  PubMed  CAS  Google Scholar 

  15. Thomas C, Nijenhuis AM, Timens W et al. Liver metastasis model of colon cancer in the rat: Immunohistochemical characterization. Invasion Metastasis 1993; 13: 102–12.

    PubMed  CAS  Google Scholar 

  16. Vahrmeijer AL, Hoetelmans RW, Mulder GJ et al. Development of resistance to glutathione depletion-induced cell death in CC531 colon carcinoma cells: association with increased expression of Bcl-2. Biochem Pharmacol 2000; 59: 1557–62.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hagenaars, M., Koelemij, R., Ensink, N.G. et al. The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma. Clin Exp Metastasis 18, 281–289 (2000). https://doi.org/10.1023/A:1011062002851

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011062002851

Navigation